Low Testosterone Linked to Aggressive Prostate Cancer Progression in Active Surveillance

A new study suggests that prostate cancer patients with low testosterone levels may face a higher risk of their cancer progressing to a more aggressive form while undergoing active surveillance. The findings, published in The Journal of Urology, indicate that baseline testosterone levels could be a valuable clinical marker for better risk stratification and tailored monitoring strategies for men choosing this approach.

Understanding Active Surveillance

Active surveillance is a recommended approach for patients with low-risk prostate cancer. It involves closely monitoring the disease, allowing physicians to delay or avoid immediate treatment unless signs of progression emerge. “Active surveillance is a safe and effective option for many men with early-stage prostate cancer. Although, identifying which patients may be more likely to experience disease progression remains a key challenge,” explains Dr. Justin R. Gregg, Associate Professor of Urology and Health Disparities Research at The University of Texas MD Anderson Cancer Center [1]. “Understanding how hormonal factors influence prostate cancer biology may help us refine surveillance strategies.”

The Study Findings

Researchers retrospectively analyzed clinical and pathologic data from over 900 men undergoing active surveillance. They discovered that patients with low baseline testosterone levels (300 ng/dL or lower) exhibited a significantly higher likelihood of their cancer progressing to grade group 3 or higher – a more aggressive form – (hazard ratio = 1.61, 95% confidence interval = 1.03–2.51, P = .04) [1]. Importantly, low testosterone was not associated with progression to grade group 2 disease or higher.

This association between low testosterone and increased progression risk persisted even after accounting for other factors such as age, prostate-specific antigen (PSA), body mass index (BMI), and tumor density and size [1].

Testosterone and Prostate Cancer: A Complex Relationship

The study emphasizes that low testosterone does not necessarily cause aggressive cancer, but rather highlights an association that could inform monitoring and treatment decisions. Research into the role of testosterone in prostate cancer has evolved significantly. Historically, it was believed that testosterone drove prostate cancer growth [2]. However, accumulating evidence suggests a more nuanced relationship. Androgens, including testosterone and dihydrotestosterone (DHT), are critical for male sexual development and prostate physiology [4].

Recent studies have even questioned the long-held belief that testosterone fuels prostate cancer, with some suggesting it may not be a primary driver of the disease [2]. Some research indicates that low testosterone levels may be associated with an increased risk of prostate cancer progression [3] and potentially with a higher risk of developing more aggressive forms of the disease.

Future Directions

The authors of the current study acknowledge the need for further research to validate these findings prospectively and to better understand the biological mechanisms linking testosterone levels to prostate cancer progression. “These findings suggest that while low testosterone is not clearly associated with moderate progression (grade group 2), it may increase the risk of higher-grade ‘extreme’ progression to grade group 3 or higher,” the authors concluded [3]. Future studies should focus on prospective validation of our findings to elucidate the biological relationship between androgens and prostate cancer progression.”

Serum testosterone also plays a pivotal role in the pathogenesis and treatment of prostate cancer, influencing tumor growth and progression [1].